MRVI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
51.4M
-21.9%
65.8M
+32.0%
49.9M
+19.8%
41.6M
-12.2%
47.4M
Cost of Revenue
30.8M
-4.2%
32.1M
-13.2%
37.0M
+2.9%
36.0M
-9.2%
39.6M
Gross Profit
20.6M
-38.7%
33.7M
+162.4%
12.8M
+127.1%
5.7M
-27.2%
7.8M
Operating Expenses
35.7M
-0.3%
35.9M
-49.9%
71.6M
+53.4%
46.7M
-37.0%
74.0M
R&D
3.7M
-4.8%
3.9M
+2.7%
3.8M
-1.5%
3.8M
-21.3%
4.9M
SG&A
32.1M
+10.2%
29.1M
-7.9%
31.6M
-10.8%
35.4M
-8.6%
38.7M
Operating Income
-15089000
-599.2%
-2158000
+96.3%
-58795000
-43.3%
-41031000
+38.1%
-66278000
EBITDA
-3340000
-127.6%
12.1M
+219.9%
-10084000
+50.7%
-20461000
+9.8%
-22672000
Net Income
-21631000
-239.2%
-6377000
+89.9%
-63015000
-39.9%
-45057000
+35.5%
-69837000
EPS (Basic)
$-0.08
-300.0%
$-0.02
+92.0%
$-0.25
-38.9%
$-0.18
+33.3%
$-0.27
EPS (Diluted)
$-0.08
-300.0%
$-0.02
+92.0%
$-0.25
-38.9%
$-0.18
+33.3%
$-0.27
Shares (Diluted)
148.0M
+1.1%
146.4M
+0.9%
145.1M
+0.3%
144.7M
+0.3%
144.2M
Maravai LifeSciences (MRVI) โ€” Financials